S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
S&P 500   3,087.01 (-0.20%)
DOW   27,691.49 (+0.04%)
QQQ   200.96 (-0.13%)
BABA   186.71 (-0.24%)
GE   11.35 (-1.48%)
T   39.37 (-0.03%)
F   9.08 (+0.44%)
ACB   3.62 (-4.99%)
PRI   129.23 (-0.37%)
BAC   33.18 (-0.24%)
DIS   136.74 (-0.88%)
Log in

BIO-TECHNE Stock Price, Forecast & Analysis (NASDAQ:TECH)

$203.08
-0.13 (-0.06 %)
(As of 11/11/2019 04:00 PM ET)
Today's Range
$202.33
Now: $203.08
$204.44
50-Day Range
$189.19
MA: $201.97
$210.39
52-Week Range
$132.75
Now: $203.08
$217.15
Volume7,688 shs
Average Volume169,298 shs
Market Capitalization$7.70 billion
P/E Ratio53.44
Dividend Yield0.63%
Beta1.22
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$714.01 million
Cash Flow$5.92 per share
Book Value$30.99 per share

Profitability

Net Income$96.07 million

Miscellaneous

Employees2,250
Market Cap$7.70 billion
Next Earnings Date2/4/2020 (Estimated)
OptionableOptionable

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.


BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions

What is BIO-TECHNE's stock symbol?

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?

BIO-TECHNE announced a quarterly dividend on Tuesday, October 29th. Shareholders of record on Friday, November 8th will be paid a dividend of $0.32 per share on Friday, November 22nd. This represents a $1.28 annualized dividend and a yield of 0.63%. The ex-dividend date is Thursday, November 7th. View BIO-TECHNE's Dividend History.

How were BIO-TECHNE's earnings last quarter?

BIO-TECHNE Corp (NASDAQ:TECH) issued its quarterly earnings results on Tuesday, October, 29th. The biotechnology company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.92 by $0.14. The biotechnology company had revenue of $183.24 million for the quarter, compared to the consensus estimate of $179.38 million. BIO-TECHNE had a return on equity of 13.36% and a net margin of 12.68%. The firm's revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.98 EPS. View BIO-TECHNE's Earnings History.

When is BIO-TECHNE's next earnings date?

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for BIO-TECHNE.

What price target have analysts set for TECH?

6 Wall Street analysts have issued 12-month price targets for BIO-TECHNE's stock. Their forecasts range from $165.00 to $270.00. On average, they expect BIO-TECHNE's share price to reach $206.80 in the next twelve months. This suggests a possible upside of 1.8% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

What is the consensus analysts' recommendation for BIO-TECHNE?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

Has BIO-TECHNE been receiving favorable news coverage?

Media coverage about TECH stock has been trending very negative on Monday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BIO-TECHNE earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for BIO-TECHNE.

Are investors shorting BIO-TECHNE?

BIO-TECHNE saw a decline in short interest in October. As of October 31st, there was short interest totalling 592,400 shares, a decline of 22.7% from the September 30th total of 766,100 shares. Based on an average trading volume of 166,300 shares, the days-to-cover ratio is presently 3.6 days. Currently, 1.6% of the company's shares are short sold. View BIO-TECHNE's Current Options Chain.

Who are some of BIO-TECHNE's key competitors?

What other stocks do shareholders of BIO-TECHNE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), Global Medical REIT (GMRE), Celgene (CELG), Gilead Sciences (GILD), Ionis Pharmaceuticals (IONS), AbbVie (ABBV), General Electric (GE), Thermo Fisher Scientific (TMO), Amgen (AMGN) and Crispr Therapeutics (CRSP).

Who are BIO-TECHNE's key executives?

BIO-TECHNE's management team includes the folowing people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
  • Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
  • Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
  • Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
  • Mr. Gerry Andros, VP of Sales and Marketing

Who are BIO-TECHNE's major shareholders?

BIO-TECHNE's stock is owned by many different of retail and institutional investors. Top institutional investors include Massachusetts Financial Services Co. MA (2.51%), First Trust Advisors LP (1.06%), Riverbridge Partners LLC (1.05%), Conestoga Capital Advisors LLC (0.86%), Kornitzer Capital Management Inc. KS (0.52%) and Candriam Luxembourg S.C.A. (0.34%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, James Hippel, John L Higgins, Norman David Eansor and Robert V Baumgartner. View Institutional Ownership Trends for BIO-TECHNE.

Which major investors are selling BIO-TECHNE stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, State of Tennessee Treasury Department, Kornitzer Capital Management Inc. KS, Tygh Capital Management Inc., Stephens Investment Management Group LLC, SG Americas Securities LLC, Conestoga Capital Advisors LLC and Rhumbline Advisers. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, James Hippel, John L Higgins and Norman David Eansor. View Insider Buying and Selling for BIO-TECHNE.

Which major investors are buying BIO-TECHNE stock?

TECH stock was purchased by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Candriam Luxembourg S.C.A., Retirement Systems of Alabama, California Public Employees Retirement System, Ascension Asset Management LLC, Comerica Bank, Summit Creek Advisors LLC and State of Alaska Department of Revenue. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

How do I buy shares of BIO-TECHNE?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIO-TECHNE's stock price today?

One share of TECH stock can currently be purchased for approximately $203.08.

How big of a company is BIO-TECHNE?

BIO-TECHNE has a market capitalization of $7.70 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

What is BIO-TECHNE's official website?

The official website for BIO-TECHNE is http://www.techne-corp.com/.

How can I contact BIO-TECHNE?

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]


MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  294 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  614
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/11/2019 by MarketBeat.com Staff

Featured Article: Why do corrections happen?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel